Never seen a more derisked biotech.
Already being used in overseas markets with solid prescription growth. Printing cash.
FDA ticked everything off except the product use label.
A team that knows how to launch products, heavily involved in sale of Anacor to Pfizer for $5.2 billion us dollars.
Extinguished royalty payments going forward.
Focus on telehealth prescriptions with major US partner signed.
Diversified future pipeline in acne, rosacea and antibiotic arms.
Insane opportunity awaits.
BOT - Anything but charting, page-6704
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.5¢ |
Change
0.015(4.55%) |
Mkt cap ! $551.2M | |||
| Open | High | Low | Value | Volume |
| 34.5¢ | 35.5¢ | 34.0¢ | $4.119M | 11.92M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 339226 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.5¢ | 416340 | 6 |
View Market Depth
| Last trade - 15.01pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
34.5¢ |
Change
0.015 ( 5.41 %) |
||||
| Open | High | Low | Volume | ||
| 34.5¢ | 35.3¢ | 34.0¢ | 6501485 | ||
| Last updated 15.24pm 17/06/2024 ? | |||||
| BOT (ASX) Chart |
